![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
RV001 (onilcamotide), peptide antigen against RhoC – is administered to patient through subcutaneous injection, encounters dendritic cells – type of white blood cell with regulatory functions in immune system – that capture, absorb and process RV001, becoming APC.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
Details:
The safety profile of RV001 (onilcamotide) was considered excellent, and the DSMC concluded that the trial can continue without modifications and can significantly prevent or delay disease progression.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
RV001, is an immuno-oncologic drug that is presented to the immune system as an antigen, stimulating T-cells to identify and destroy cells that carry this protein, i.e. metastatic or metastatic potential cells.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2021
Details:
The objective of the study is to show that RV001 can significantly prevent or delay disease progression in these patients, something for which no standard therapy is available today.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 09, 2021
Details:
The objective of the development of RV001 is to prevent/delay the recurrence of cancer and its progression to a metastatic state. If a clinical proof of concept is obtained in prostate cancer, several other cancer indications would also be candidates for development.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
RhoVac reported that as Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination causing a delay in RhoVac's Phase IIb study.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
BRaVac is a phase IIb randomized, placebo controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment.
Lead Product(s): RV001,Montanide ISA 51
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The scientifically reviewed article reports that the treatment with RhoVac’s drug candidate RV001 was safe and well tolerated, and that a long-lasting immune response could be generated in the vast majority of patients.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The article will feature an elaboration on the mode of action of RV001, but also a discussion on the PSA data findings indicating possibilities of delaying disease progression, for which RhoVac’s currently ongoing phase IIb study is aimed at providing substantial evidence.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
The phase IIb-study is a randomized, placebo-controlled and double-blind study, with the primary objective of evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 17, 2020
Details:
First patient in the USA is included in RhoVac’s BRaVac study. BraVac is a randomized, placebo controlled and double-blind study which aims to evaluate if treatment with RV001 can prevent or limit the development of advanced prostate cancer after curative intent treatment.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
Details:
BRaVac is a randomized, placebo-controlled and double-blind study, with the primary study aim to evaluate whether treatment with the drug candidate RV001 can prevent or limit the development of metastatic cancer after surgery or radiation of the prostate.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: RV001
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
First patient is being treated in BRaVac trial. This phase IIb-study clinical trial tests the effectiveness of RV001 in preventing the development after curative treatment of advanced prostate cancer.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2020
Details:
Company seeing signs of delays in the ongoing clinical phase IIb study with the drug candidate RV001 in prostate cancer, due to the Covid-19 pandemic.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 02, 2020
Details:
BRaVac is aimed at evaluating if treatment with the drug candidate RV001 can prevent or limit the development of advanced prostate cancer after curative treatment.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2020
Details:
The phase IIb study is an international, multicenter study, which is expected to recruit more than 175 patients in EU, as well as in the United States.
Lead Product(s): RV001
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2020